| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.26 | 4e-10 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.22 | 7e-10 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-09 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.19 | 1e-09 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-09 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-09 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-08 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-08 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-07 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-07 |